Clinical and angiographic profile of symptomatic patients undergoing percutaneous transluminal coronary angioplasty and drug-eluting  stent implantation

V.S.R. Bhupal; P. Sampath Kumar

doi:10.18203/2320-6012.ijrms20194316

Authors

V.S.R. Bhupal Department of Cardiology, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, Chinoutpalli, Vijayawada, Andhra Pradesh, India
P. Sampath Kumar Department of Cardiology, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, Chinoutpalli, Vijayawada, Andhra Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20194316

Keywords:

Drug-eluting stent, In-stent restenosis, Percutaneous coronary intervention, Percutaneous coronary transluminal angioplasty

Abstract

Background: There are limited number of studies in India which have looked at this clinical and angiographic characteristic of the disease. Thus, this study was conducted to assess the clinical and angiographic profile of symptomatic patients who underwent percutaneous transluminal coronary angioplasty (PTCA) and drug-eluting stent (DES) implantation.

Methods: This was an observational study conducted at a tertiary-care center in India between November 2014 and November 2015. A total of 106 consecutive patients who received either Cypher/Xience/BioMime stent presented with anginal symptoms were included in the study. Based on the type of stent received, patients were divided into two groups: (A) Limus group; (B) Paclitaxel group. Coronary angiogram was done in all the patients. Angioplasty data were collected from patient records. Angiographic profiles of the two groups were compared and analysed.

Results: Among the 106 patients, 54 patients were included in the Limus group and 52 patients were included in the Taxus stent. De novo lesions were found to be significantly higher in the Limus group (40(74%), p = 0.06) whereas the in-stent restenosis was found to be significantly higher in the paclitaxel group (22(42.3%), p = 0.08). At follow-up, the incidence of death was 0% and no patients suffered by myocardial infarction. One (1.8%), two (3.8%) patients from the Limus and Paclitaxel groups had target vessel revascularization, respectively.

Conclusions: Development of lesions in new areas rather than in-stent restenosis is the cause for angina in the majority of patients who underwent angioplasty presenting with anginal symptoms.

Metrics

Metrics Loading ...

References

Praveen S, Baiju R, Radhakrishnan VV, Kumar SKK. Predictors of angiographic restenosis in patients with coronary artery disease who have undergone percutaneous coronary intervention with drug eluting stents. Int J Res Med Sci. 2018;6(2):448-54.

Sanjeev Sanghvi AK, Rohit Mathur, Anil Baroopal. Clinical and angiographic profile in patients of western Rajasthan undergoing percutaneous coronary interventions: a single centre experience. Int J Res Med Scie. 2018 September;6:3124-31.

Aldea GS, Mokadam NA, Melford Jr R, Stewart D, Maynard C, Reisman M, et al. Changing volumes, risk profiles, and outcomes of coronary artery bypass grafting and percutaneous coronary interventions. Ann Thor Surg. 2009;87(6):1828-38.

Morice MC, Serruys PW, Kappetein AP, Feldman TE,Stahle E, Colombo A, et al. Outcomes in patients with de novo left main disease treated with either PCI using paclitaxel-eluting stents or CABG treatment in the SYNTAX trial. Circulation. 2010;24:2645-53.

Beig JR, Shah TR, Hafeez I, Dar MI, Rather HA, Tramboo NA, et al. Clinico-angiographic profile and procedural outcomes in patients undergoing percutaneous coronary interventions: The Srinagar registry. Indian Heart J. 2017;69(5):589-96.

Mabin TA, Holmes Jr DR, Smith HC, Vlietstra RE, Reeder GS, Bresnahan JF, et al. Follow-up clinical results in patients undergoing percutaneous transluminal coronary angioplasty. Circulation. 1985 Apr;71(4):754-60.

Kaltenbach M, Kober G, Scherer D, Vallbracht C. Recurrence rate after successful coronary angioplasty. Eur Heart J. 1985;6(3):276-81.

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New Engl J Med. 2003;349(14):1315-23.

Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New Engl J Medi. 2004;350(3):221-31.

Xavier D, Pais P, Devereaux P, Xie C, Prabhakaran D, Reddy KS, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008;371(9622):1435-42.

Jose VJ, Gupta SN. Mortality and morbidity of acute ST segment elevation myocardial infarction in the current era. Ind Heart J. 2004;56(3):210-4.

Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. New Engl J Med. 2007;356(15):1503-16.

Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) study. Circulation. 2004;109(11):1366-70.

Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006;113(19):2293-300.

Abhayankar A, Sandhu MS, Polavrapu RS. Twelve-month comparative analysis of clinical outcomes using biodegradable polymer-coated everolimus-eluting stents versus durable polymer-coated everolimus-eluting stents in all-comers patients. Ind Heart J. 2019 Mar-Apr;71(2):149-54.

Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. New Engl J Med. 1994;331(8):489-95.

Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus-or paclitaxel-eluting stents. J Am College of Cardiol. 2006;48(7):1304-09.

Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am College of Cardiol. 2007;50(12):1123-31.

Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. New England J Medi 2005;353(7):663-70.

Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-eluting versus paclitaxel-eluting stents in percutaneous coronary intervention: meta-analysis of randomized trials. Thrombosis. 2012 May 9;2012.